Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 3:9:603.
doi: 10.3389/fonc.2019.00603. eCollection 2019.

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

Valentín García-Gutiérrez  1 , Juan Carlos Hernández-Boluda  2
Affiliations
Review

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety

Valentín García-Gutiérrez et al. Front Oncol. .

Abstract

Chronic myeloid leukemia (CML) is currently a disease in which patients can enjoy a near normal life-expectancy. However, since the majority of patients will need to remain on treatment indefinitely, physicians in care of CML patients need be familiar with the indications and toxicities of all approved tyrosine kinase inhibitors (TKI). In clinical practice, there are five TKI (imatinib, nilotinib, dasatinib, bosutinib, and ponatinib) that are available in different scenarios and have distinct safety profiles. Decisions regarding first line treatment must be based on CML risk, comorbidities, and patients expectations. Despite the excellent outcome, half of the patients will eventually fail (due to intolerance or resistance) to first line treatment, with many of them requiring a third or even further lines of therapy. When selecting for such patients, it is essential to distinguish between failure and intolerance to previous TKIs. In the present review, we will address all these issues from a practical point of view.

Keywords: chronic myeloid leukemia; efficacy; patients; safety; treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. . Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. (2017) 376:917–27. 10.1056/NEJMoa1609324 - DOI - PMC - PubMed
    1. Sasaki K, Strom SS, O'Brien S, Jabbour E, Ravandi F, Konopleva M, et al. . Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol. (2015) 2:e186–93. 10.1016/S2352-3026(15)00048-4 - DOI - PMC - PubMed
    1. Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, et al. . Chronic myeloid leukemia: reminiscences and dreams. Haematologica. (2016) 101:541–8. 10.3324/haematol.2015.139337 - DOI - PMC - PubMed
    1. Baccarani M. Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence. Leukemia. (2017) 31:1015–6. 10.1038/leu.2017.20 - DOI - PubMed
    1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. . European leukemianet recommendations for the management of chronic myeloid leukemia: 2013. Blood. (2013) 122:872–4. 10.1182/blood-2013-05-501569 - DOI - PMC - PubMed

LinkOut - more resources